UCB reports new EADV 2026 data supporting earlier use of Bimzelx in hidradenitis suppurativa

UCB SA said new data at EADV 2026 supports earlier use of Bimzelx (bimekizumab) for hidradenitis suppurativa, including improved draining tunnel outcomes in biologic-naive patients and three-year quality-of-life improvements.